Today, FDA Administrator Dr. Marty Makary announced his resignation from the agency. After this announcement, Dr. Jeff Singer, a senior fellow at the Cato Institute, released the following statement:
“Dr. Makary brought a needed skepticism toward bureaucratic inertia at the FDA and often showed a willingness to challenge regulatory orthodoxy. As a fellow surgeon and longtime advocate for greater transparency and market-oriented reform in health care, I appreciated his efforts to reduce unnecessary barriers to innovation and patient access, though I sometimes wished those efforts had gone further.
“During his tenure, he challenged many of medicine’s blind spots, though he also had some of his own—particularly on issues such as vaping, kratom, 7‑OH, and opioid policy, where I often disagreed with him. Still, I have always regarded him as someone willing to question entrenched assumptions, a quality that is increasingly rare in modern health policy.”
To speak with Dr. Singer about Dr. Makary’s departure, contact Christopher Tarvardian.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.